Yannis Paloyelis1, Orla M Doyle2, Fernando O Zelaya2, Stefanos Maltezos3, Steven C Williams2, Aikaterini Fotopoulou4, Matthew A Howard2. 1. Departments of Neuroimaging, Institute of Psychiatry, King's College London, London. Electronic address: Yannis.Paloyelis@kcl.ac.uk. 2. Departments of Neuroimaging, Institute of Psychiatry, King's College London, London. 3. Departments of Forensic and Neurodevelopmental Science, Institute of Psychiatry, King's College London, London. 4. Research Department of Clinical, Educational, and Health Psychology, University College London, London, United Kingdom.
Abstract
BACKGROUND: Animal and human studies highlight the role of oxytocin in social cognition and behavior and the potential of intranasal oxytocin (IN-OT) to treat social impairment in individuals with neuropsychiatric disorders such as autism. However, extensive efforts to evaluate the central actions and therapeutic efficacy of IN-OT may be marred by the absence of data regarding its temporal dynamics and sites of action in the living human brain. METHODS: In a placebo-controlled study, we used arterial spin labeling to measure IN-OT-induced changes in resting regional cerebral blood flow (rCBF) in 32 healthy men. Volunteers were blinded regarding the nature of the compound they received. The rCBF data were acquired 15 min before and up to 78 min after onset of treatment onset (40 IU of IN-OT or placebo). The data were analyzed using mass univariate and multivariate pattern recognition techniques. RESULTS: We obtained robust evidence delineating an oxytocinergic network comprising regions expected to express oxytocin receptors, based on histologic evidence, and including core regions of the brain circuitry underpinning social cognition and emotion processing. Pattern recognition on rCBF maps indicated that IN-OT-induced changes were sustained over the entire posttreatment observation interval (25-78 min) and consistent with a pharmacodynamic profile showing a peak response at 39-51 min. CONCLUSIONS: Our study provides the first visualization and quantification of IN-OT-induced changes in rCBF in the living human brain unaffected by cognitive, affective, or social manipulations. Our findings can inform theoretical and mechanistic models regarding IN-OT effects on typical and atypical social behavior and guide future experiments (e.g., regarding the timing of experimental manipulations).
RCT Entities:
BACKGROUND: Animal and human studies highlight the role of oxytocin in social cognition and behavior and the potential of intranasal oxytocin (IN-OT) to treat social impairment in individuals with neuropsychiatric disorders such as autism. However, extensive efforts to evaluate the central actions and therapeutic efficacy of IN-OT may be marred by the absence of data regarding its temporal dynamics and sites of action in the living human brain. METHODS: In a placebo-controlled study, we used arterial spin labeling to measure IN-OT-induced changes in resting regional cerebral blood flow (rCBF) in 32 healthy men. Volunteers were blinded regarding the nature of the compound they received. The rCBF data were acquired 15 min before and up to 78 min after onset of treatment onset (40 IU of IN-OT or placebo). The data were analyzed using mass univariate and multivariate pattern recognition techniques. RESULTS: We obtained robust evidence delineating an oxytocinergic network comprising regions expected to express oxytocin receptors, based on histologic evidence, and including core regions of the brain circuitry underpinning social cognition and emotion processing. Pattern recognition on rCBF maps indicated that IN-OT-induced changes were sustained over the entire posttreatment observation interval (25-78 min) and consistent with a pharmacodynamic profile showing a peak response at 39-51 min. CONCLUSIONS: Our study provides the first visualization and quantification of IN-OT-induced changes in rCBF in the living human brain unaffected by cognitive, affective, or social manipulations. Our findings can inform theoretical and mechanistic models regarding IN-OT effects on typical and atypical social behavior and guide future experiments (e.g., regarding the timing of experimental manipulations).
Authors: Sergey Shcherbinin; Orla Doyle; Fernando O Zelaya; Sara de Simoni; Mitul A Mehta; Adam J Schwarz Journal: Psychopharmacology (Berl) Date: 2015-07-31 Impact factor: 4.530
Authors: Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven Journal: Hum Brain Mapp Date: 2017-02-01 Impact factor: 5.038
Authors: Saskia B J Koch; Mirjam van Zuiden; Laura Nawijn; Jessie L Frijling; Dick J Veltman; Miranda Olff Journal: Neuropsychopharmacology Date: 2016-01-07 Impact factor: 7.853
Authors: Saskia Bj Koch; Mirjam van Zuiden; Laura Nawijn; Jessie L Frijling; Dick J Veltman; Miranda Olff Journal: Neuropsychopharmacology Date: 2015-09-25 Impact factor: 7.853
Authors: Jessie L Frijling; Mirjam van Zuiden; Saskia B J Koch; Laura Nawijn; Dick J Veltman; Miranda Olff Journal: Neuropsychopharmacology Date: 2015-08-31 Impact factor: 7.853
Authors: Lin W Hung; Sophie Neuner; Jai S Polepalli; Kevin T Beier; Matthew Wright; Jessica J Walsh; Eastman M Lewis; Liqun Luo; Karl Deisseroth; Gül Dölen; Robert C Malenka Journal: Science Date: 2017-09-28 Impact factor: 47.728